Polypharmacy and Associated Risk Factors and Clinical Outcomes for Surgical Patients Discharged From Hospital

NCT04805151 | Active Not Recruiting

• 1 other identifier: UI- 2021 polypharmacy
• Study Type: observational
• Target: 56,000
• Locations: 1 country
• Sites: 1

Brief Summary

The World Health Organisation Patient Safety Challenge: Medication Without Harm has brought our attention to the importance of medication-related harm as a global public health issue. One of the major contributing factors is polypharmacy, the usage of multiple medicines at the same time. People are getting older and living longer with chronic diseases; they need more medications, which frequently leads to polypharmacy. Subsequently, they are at more risk of medication-related harm. The planned project is an epidemiological study on polypharmacy, medication appropriateness, risk factors, and clinical outcomes post-discharge from a hospital for surgical patients. The study group hypothesise that pre-and post-operative polypharmacy and potentially inappropriate prescribing is common, especially among older patients, patients with a high comorbidity and frailty burden, and patients undergoing more complicated surgery. Our hypothesis is additionally that preoperative polypharmacy and potentially inappropriate prescribing is associated with a higher short- and long-term mortality, a longer primary hospitalization length of stay, and a higher risk of readmission.

Conditions

Polypharmacy; General Surgery

Keywords

Polypharmacy; Potentially inappropriate medication list; Drug-related side effects and adverse reaction; Readmission; Patient discharge; Prediction tool; Start and stop; Inappropriate Prescribing; General surgery; Beers criteria; STOPP START criteria

Outcome Measures

Primary Outcomes (1)

• Polypharmacy

  Prevalence of polypharmacy (≥5 or more regular medicines) and hyper-polypharmacy (≥10 regular medicines) pre-admission and prevalence and incidence post-discharge for surgery patients ≥18 years in Iceland

  2010-2018

Secondary Outcomes (1)

• Clinical variables associated with the prevalence and incidence of polypharmacy

  2010-2018

Interventions

No intervention OTHER

No intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population is surgical patients in hospital settings. The cohort will include 100% of tertiary care surgical admissions in Iceland and 70-80% of secondary care in Iceland. The study population includes 56.000 number of participants.

You may qualify if:

• Participants: surgery patients ≥18 years in admitted to Landspitali University Hospital over the period 2010-2018.

You may not qualify if:

• Under 18 years of age

Sponsors & Collaborators

• University of Iceland: lead
• Landspitali University Hospital: collaborator

Study Sites (1)

Faculty of Pharmaceutical Sciences

Reykjavik, Iceland

Location

Related Publications (1)

• Jonsdottir F, Blondal AB, Guethmundsson A, Bates I, Stevenson JM, Sigurethsson MI. Epidemiology and association with outcomes of polypharmacy in patients undergoing surgery: retrospective, population-based cohort study. BJS Open. 2023 May 5;7(3):zrad041. doi: 10.1093/bjsopen/zrad041.

  PMID: 37194458 DERIVED

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Study Officials

• Martin Sigurdsson, MD PhD

  University of Iceland

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2021
• First Posted: March 18, 2021
• Study Start: January 2, 2021
• Primary Completion: June 2, 2024
• Study Completion: January 2, 2025
• Last Updated: February 9, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

IC (1)